137 related articles for article (PubMed ID: 38508444)
21. Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells.
Starenki D; Sosonkina N; Hong SK; Lloyd RV; Park JI
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027376
[TBL] [Abstract][Full Text] [Related]
22. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
[TBL] [Abstract][Full Text] [Related]
23. Dyserythropoiesis of myelodysplastic syndromes.
Lefèvre C; Bondu S; Le Goff S; Kosmider O; Fontenay M
Curr Opin Hematol; 2017 May; 24(3):191-197. PubMed ID: 28072603
[TBL] [Abstract][Full Text] [Related]
24. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.
Tehranchi R; Invernizzi R; Grandien A; Zhivotovsky B; Fadeel B; Forsblom AM; Travaglino E; Samuelsson J; Hast R; Nilsson L; Cazzola M; Wibom R; Hellström-Lindberg E
Blood; 2005 Jul; 106(1):247-53. PubMed ID: 15755901
[TBL] [Abstract][Full Text] [Related]
25. Deletion 5q MDS: molecular and therapeutic implications.
Komrokji RS; Padron E; Ebert BL; List AF
Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
[TBL] [Abstract][Full Text] [Related]
26. Alteration of lipids and the transcription of lipid-related genes in myelodysplastic syndromes via a TP53-related pathway.
Ellis MH; Baraf L; Shaish A; Har-Zahav A; Harats D; Ashur-Fabian O
Exp Hematol; 2012 Jul; 40(7):540-547.e1. PubMed ID: 22381680
[TBL] [Abstract][Full Text] [Related]
27. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
28. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
Nilsson L; Astrand-Grundström I; Anderson K; Arvidsson I; Hokland P; Bryder D; Kjeldsen L; Johansson B; Hellström-Lindberg E; Hast R; Jacobsen SE
Blood; 2002 Jul; 100(1):259-67. PubMed ID: 12070035
[TBL] [Abstract][Full Text] [Related]
29. Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
Dimitriou M; Woll PS; Mortera-Blanco T; Karimi M; Wedge DC; Doolittle H; Douagi I; Papaemmanuil E; Jacobsen SE; Hellström-Lindberg E
Oncotarget; 2016 Nov; 7(45):72685-72698. PubMed ID: 27683035
[TBL] [Abstract][Full Text] [Related]
30. Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability.
Wu PK; Hong SK; Starenki D; Oshima K; Shao H; Gestwicki JE; Tsai S; Park JI
Oncogene; 2020 May; 39(21):4257-4270. PubMed ID: 32291414
[TBL] [Abstract][Full Text] [Related]
31. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.
Venner CP; Woltosz JW; Nevill TJ; Deeg HJ; Caceres G; Platzbecker U; Scott BL; Sokol L; Sung S; List AF; Karsan A
Haematologica; 2013 Mar; 98(3):409-13. PubMed ID: 22929976
[TBL] [Abstract][Full Text] [Related]
32. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
[TBL] [Abstract][Full Text] [Related]
33. Acute Myeloid Leukemia and Myelodysplastic Syndromes with
Sill H; Zebisch A; Haase D
Clin Cancer Res; 2020 Oct; 26(20):5304-5309. PubMed ID: 32816950
[TBL] [Abstract][Full Text] [Related]
34. Recurrent Abnormal Clones in Myelodysplastic Syndrome Marrow Originate from Cells at a Pluripotent Stem Level and Maintain Their Early Differentiation Potency.
Qi H; Qingxia Z; Xiao L; Lingyun W; Feng X; Zheng Z; Chunkang C
Cancer Invest; 2015; 33(8):369-77. PubMed ID: 26135215
[TBL] [Abstract][Full Text] [Related]
35. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
Chan O; Ali NA; Sallman D; Padron E; Lancet J; Komrokji R
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e467-e476. PubMed ID: 35101379
[TBL] [Abstract][Full Text] [Related]
37. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
38. SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS.
Huang Y; Hale J; Wang Y; Li W; Zhang S; Zhang J; Zhao H; Guo X; Liu J; Yan H; Yazdanbakhsh K; Huang G; Hillyer CD; Mohandas N; Chen L; Sun L; An X
J Hematol Oncol; 2018 Feb; 11(1):19. PubMed ID: 29433555
[TBL] [Abstract][Full Text] [Related]
39. Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
Buesche G; Teoman H; Schneider RK; Ribezzo F; Ebert BL; Giagounidis A; Göhring G; Schlegelberger B; Bock O; Ganser A; Aul C; Germing U; Kreipe H
Br J Haematol; 2022 Jul; 198(1):114-130. PubMed ID: 35362549
[TBL] [Abstract][Full Text] [Related]
40. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).
Saft L; Karimi M; Ghaderi M; Matolcsy A; Mufti GJ; Kulasekararaj A; Göhring G; Giagounidis A; Selleslag D; Muus P; Sanz G; Mittelman M; Bowen D; Porwit A; Fu T; Backstrom J; Fenaux P; MacBeth KJ; Hellström-Lindberg E
Haematologica; 2014 Jun; 99(6):1041-9. PubMed ID: 24682512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
